ACTRIMS Forum meeting – West Palm Beach, Florida – February 27 – March 1, 2025
Please note that the NeuroSens ACTRIMS Forum 2025 Highlights slide resource, developed in collaboration with Dr. Mark S. Freedman, Director of the MS Research Unit, The Ottawa Hospital, Ottawa, is now available on request only. Healthcare professionals can request this slide presentation for self-study (view only) by completing the online form. For more information, contact us at info@neuro-sens.com. Read More
Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
D.C. is a 41-year-old woman diagnosed with multiple sclerosis 14 years ago. She was treated initially with a beta interferon. She experienced ongoing disease activity and was transitioned to natalizumab 10 years ago. She was completely stable for six years. She was switched to fingolimod after a significant change in JCV index. She had no MRI changes on natalizumab and a few new MRI lesions on fingolimod. She had no new lesions while on natalizumab and few MRI changes on fingolimod. Her EDSS score a year ago was 1.5 (vision 1, sensory 1, bladder 1). Read More